Study Explores Impact of Diet and Gut Microbiome on Immunotherapy Effectiveness

The gut microbiome has emerged as a vital player in regulating antitumor immunity, while epidemiological studies have suggested that patients with higher body mass index (BMI) tend to have better responses to ICIs. However, the reason behind this correlation is not fully understood.

A landmark study titled “Diet–microbiome synergy underlies obesity-associated immunotherapy efficacy,” published in Nature by a team including Lysanne Desharnais and others, provides important insights. The research indicates that it is not obesity in itself that improves immunotherapy response, but rather the interaction between diet and the gut microbiome.

The gut microbiome, a complex ecosystem of microorganisms residing in the gastrointestinal tract, has moved beyond its historical role in digestion to being recognized as a major influencer of immune health. Microbial metabolites interact with immune cells, affecting various immune processes such as T-cell activation and cytokine production. Research has shown that favorable gut microbiota can enhance the efficacy of PD-1 or PD-L1 inhibitors, while disruptions in microbiome health have been linked to poorer outcomes.

The so-called “obesity paradox” poses an intriguing question, as many retrospective studies indicate that overweight and obese patients often show improved responses to ICIs. Yet, obesity is associated with multiple health issues, such as chronic inflammation and metabolic dysfunction, complicating the link between body weight and treatment outcomes.

Desharnais and colleagues aimed to investigate whether obesity itself or other biological factors were responsible for improved responses to immunotherapy.

To do this, the researchers designed an extensive dietary model, analyzing 12 distinct diets ranging from high-fat and Western diets to Mediterranean, vegan, and ketogenic options. This allowed them to separate the influences of body weight from those of dietary composition. Mice were placed on these diets before receiving anti-PD-1 therapy, and various factors including immune cell populations and treatment responses were thoroughly evaluated.

The results revealed that body weight and metabolic issues were not reliable predictors of immunotherapy outcomes. While some diets led to improved efficacy of anti-PD-1 therapy, others did not, suggesting that dietary composition is the key factor in determining the effectiveness of immune checkpoint inhibitors. The researchers concluded that the interaction between diet and the gut microbiome better explains the obesity paradox than BMI alone.

Sequencing analyses indicated significant differences in the fecal microbiomes of different dietary groups. Mice that responded well to the therapy exhibited microbiomes enriched in bacteria supporting immune activation, whereas resistant groups showed distinct microbial compositions. The research identified Lactobacillus johnsonii as a key bacterial species linked to successful immunotherapy outcomes. However, the mere presence of this bacterium was not enough; its beneficial effects were most pronounced when combined with a supportive diet.

To further test the relationship between diet and treatment response, diet-switch experiments were conducted. Mice initially resistant to anti-PD-1 therapy became responsive after switching to a favorable diet just before treatment, highlighting the rapid changes in immune response due to dietary modifications. This was further supported by findings from fecal microbiota transplantation, indicating that the diet significantly influences whether transplanted microbial communities can establish an effective ecosystem for immune support.

Metabolomic analyses revealed that certain microbial metabolites, particularly those derived from favorable dietary patterns, enhance the function of cytotoxic T cells. Notably, desaminotyrosine (DAT) emerged as a key metabolite that could boost T-cell activity and restore immunotherapy sensitivity in resistant dietary models.

The study’s implications extend beyond laboratory findings. The authors suggest integrating nutritional strategies into immunotherapy plans to potentially enhance outcomes. Future possibilities include personalized nutritional interventions, targeted gut microbiome manipulation, and the development of therapies based on microbial metabolites.

Overall, this research shifts the focus from solely BMI to a deeper understanding of how diet and the gut microbiome interact with the immune system, potentially paving the way for personalized approaches in cancer immunotherapy.